Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

9.10USD
4:00pm EDT
Change (% chg)

$0.60 (+7.06%)
Prev Close
$8.50
Open
$8.45
Day's High
$9.55
Day's Low
$8.20
Volume
130,566
Avg. Vol
27,533
52-wk High
$9.55
52-wk Low
$5.60

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $178.29
Shares Outstanding(Mil.): 20.97
Dividend: --
Yield (%): --

Financials

  ALDX.OQ Industry Sector
P/E (TTM): -- 108.45 32.71
EPS (TTM): -1.57 -- --
ROI: -94.30 1.54 12.72
ROE: -97.44 0.30 14.84

BRIEF-Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 10 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

Apr 24 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.88 +0.90
Novartis AG (NOVN.S) CHF81.88 -0.06
Pfizer Inc. (PFE.N) $44.06 +0.31
AbbVie Inc (ABBV.N) $92.26 -0.42
Amgen, Inc. (AMGN.OQ) $205.10 0.00
Bristol-Myers Squibb Co (BMY.N) $62.25 +0.50
Bristol-Myers Squibb Co (BMYMP.PK) $1,034.45 --
UCB SA (UCB.BR) €77.90 +0.06

Earnings vs. Estimates